Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD- (L) 1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago

Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD- (L) 1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago — alphai